Trial Profile

Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenecteplase (Primary) ; Alteplase
Indications Stroke
Focus Therapeutic Use
Acronyms NOR-TEST

Most Recent Events

01 May 2019 Post Hoc analysis results (n=348) assessing the rates of favorable outcome at 90 days, symptomatic intracerebral hemorrhage (sICH), and mortality after 7 and 90 days between tenecteplase and alteplase are published in the Stroke
03 Jan 2019 Results of prespecified substudy of NOR-TEST assessing efficacy and safety of tenecteplase and alteplase in patients treated 3 to 4.5 hours after ischemic stroke, published in the Stroke.
19 Jun 2018 Results of post-hoc analysis presented at the 4th Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com